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In 2000, a reference center was created to systemati-
cally record leishmaniases in Germany. We analyzed 58
cases of leishmaniases imported during a 2-year period.
These findings will serve as a baseline for the sandfly vec-
tor’s anticipated northward move because of global warm-
ing and as an advisory for immunocompromised persons
traveling to leishmaniasis-endemic areas.
L
eishmaniases compose a spectrum of protozoal dis-
eases currently endemic in 88 countries in Asia,
Africa, the Americas, and southern Europe. The geograph-
ic distribution of leishmaniases has widened, and the dis-
ease is reported in areas in which leishmaniasis was previ-
ously nonendemic (1). Apart from cutaneous, mucocuta-
neous/mucosal, and visceral leishmaniases, HIV-1–associ-
ated leishmaniasis acquired in southern Europe and in
other parts of the world have been observed in increasing
numbers (1,2).
Leishmaniasis is not notifiable in Germany. In
September 2000, a national advice and reference center
was created at the Institute of Tropical Medicine in Berlin;
the aim of the center was to monitor the frequency, origin,
and type of leishmaniases seen in Germany; to advise
physicians; and to improve information for travelers to dis-
ease-endemic areas. The healthcare professionals were
informed about the reference center by the Robert-Koch-
Institute, the center for surveillance of infectious diseases
in Germany, as well as through the Journal of the German
Medical Association, which is received by every registered
physician (3). Leishmaniasis was diagnosed if parasites
were detected in smears, culture, histologic sections, by
polymerase chain reaction (PCR) of lesion biopsy speci-
mens, bone marrow, or peripheral blood. For detection of
Leishmania-specific antigen the small subunit (ssu rRNA),
the internal transcribed spacer (ITS-1) region of the ribo-
somal RNA genes, or both, were amplified by PCR (4).
Leishmania complexes and species were determined by
digestion of the ribosomal ITS-1 PCR product with restric-
tion enzymes (4). 
Within 2 years, 70 cases of leishmaniases (43 cutaneous
or mucocutaneous/mucosal; 27 visceral) were reported.
For 58 case-patients (35 cutaneous or mucocutaneous/
mucosal; 23 visceral), data were available on the age, sex,
residence, travel destination, possible exposure location,
reason for travel, duration of stay, duration and type of
symptoms, concomitant diseases or therapies, type of diag-
nosis, and treatment received. 
Cutaneous and Mucosal Leishmaniasis
Of the 35 patients with cutaneous or mucocutaneous/
mucosal leishmaniasis, 30 were German tourists (Table 1).
The male-to-female ratio was 1.5:1. Ten had contracted
cutaneous or mucocutaneous/mucosal leishmaniasis in
Europe, 11 in Central and South America, 6 in Asia, and 3
in Africa. Two persons had been infected during work
stays of 1 to 4 months in French Guyana, one each in Peru
and Libya, and one patient had immigrated from
Afghanistan.
The median duration of lesions until the diagnosis of
leishmaniasis was made was 4 months (range 3 weeks to 2
years). Sixteen patients had more than one lesion (median
2, range 1–6 lesions). Seventeen lesions were located in
the face, including mouth and nose, 28 on the upper
extremities and 21 on the lower extremities. Lesions were
ulcerated in 39 cases, papular-nodular in 24, and plaque-
like in 3. Parasites were detected in 13 of 20 smears, in 9
of 10 cultures, and in 14 of 16 histologic sections; by using
PCR, Leishmania-specific DNA was detected in 16 of 16
biopsy specimens. 
Patient 1 had lesions in the mouth caused by L. infan-
tum. She was under continuous immunosuppressive treat-
ment for severe bronchial asthma. Patient 2 had received
methotrexate and steroids for treatment of systemic col-
lagenosis for several weeks. Both patients were tested for
leishmanial infection in the blood; in both patients, the
Leishmania-specific PCR of the buffy coat of the blood
was positive. Patient 22 had mucocutaneous leishmaniasis
of the nasal septum. She had been treated for a skin lesion
caused by L. braziliensis 3 years earlier. 
Visceral Leishmaniasis
A total of 18 of the 23 visceral leishmaniasis patients
were German tourists; 3 were immigrants from Angola,
Iran, and Togo; and 2 were visitors from Italy and Portugal
(Table 2). The male-to-female ratio was 6.7:1.
The median time between symptom onset and the cor-
rect diagnosis was 4 months (range 1–16 months). All
case-patients had fever, 17 (74%) had splenomegaly, 11
(48%) hepatomegaly, 20 (87%) anemia, 17 (74%) leukope-
nia, and 8 (35%) thrombocytopenia.
Bone marrow smears indicated Leishmania in 18 of 20,
bone marrow culture in 6 of 7, bone marrow histologic
sections in 7 of 8, PCR of the bone marrow in 8 of 9, and
PCR of the buffy coat of the blood in 7 of 7 cases.
Additionally, antibodies were detected in medium to high
concentration by an immunofluorescence test, enzyme-
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cases. Species was identified in 7 of 18 visceral cases con-
tracted in southern Europe and indicated Leishmania
belonging to the L. donovani complex, which implicated
infection with L. infantum. 
Six cases of visceral leishmaniasis occurred in children
2 months of age to 11 years of age. Four German tourists
and two immigrants had long-known HIV infection (medi-
an duration 3 years, range 8 months–6 years). All HIV–co-
infected patients had CD4-cell counts below 200/µL
(median 108, range 23–185 CD4 cells/µL) when the diag-
nosis of visceral leishmaniasis was made. Of the remaining
11 patients, 1 had a thymoma with impaired T-helper-1 cell
function, 2 had received intermittent immunosuppressive
therapy (methotrexate and steroids) for rheumatologic dis-
ease, and 2 patients had their spleens removed. Three
patients were in an impaired general condition because of
combinations of diabetes, hypertonus, hypercholes-
terolemia, and emphysema. In the remaining three patients
(53–68 years of age), apart from hypertonus in one, no
impairing condition was detected. 
Discussion
Information on single cases and a small case series of
imported leishmaniases in Germany is available, but sys-
tematic reporting on frequency, type, and origin of leish-
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Table 1. Characteristics of patients with cutaneous and mucosal leishmaniasis, Germany  
No.  Exposure  Status  Sex  Age (y)  Leishmania species  Treatment  Outcome 
Europe   
1  France  Tourist  F  64  L. donovani complex  No treatment  No cure 
2  Italy  Tourist  F  24  L. donovani complex  Liposomal amphotericin B  Improved 
3  Malta  Tourist  M  22  L. donovani complex  Perilesional pentavalent antimonials  Cured 
4  Malta  Tourist  M  39  L. donovani complex  Perilesional pentavalent antimonials  Cured 
5  Malta  Tourist  F  57  n.d.  Perilesional pentavalent antimonials  Cured 
6  Malta  Tourist  M  62  n.d.  Perilesional pentavalent antimonials  Cured 
7  Spain (Majorca)  Tourist  F  5  n.d.  Pentamidine isethionate  Cured 
8  Spain (Majorca)  Tourist  M  13  L. donovani complex  Perilesional pentavalent antimonials  Cured 
9  Spain  Tourist  F  31  L. donovani complex  No treatment  Unknown 
10  Spain  Tourist  M  33  L. donovani complex  Antibiotic  Cured 
Americas   
11  Belize  Tourist  M  36  L. braziliensis complex  Liposomal amphotericin B  Unknown 
12  Belize  Tourist  F  32  n.d.  IFN-gamma  Cured 
13  Bolivia  Tourist  M  35  L. braziliensis complex  Liposomal amphotericin B  Unknown 
14  Brazil  Tourist  M  25  n.d.  Systemic pentavalent antimonials  Cured 
15  Brazil  Tourist  M  39  L. braziliensis complex  Liposomal amphotericin B  Unknown 
16  Brazil  Tourist  M  33  L. braziliensis complex  Liposomal amphotericin B  Cured 
17  Ecuador  Tourist  F  29  L. braziliensis complex  Liposomal amphotericin B  Cured 
18  Ecuador  Tourist  M  36  n.d.  Liposomal amphotericin B  Cured 
19  French Guyana  Work stay  M  28  L. braziliensis complex  Liposomal amphotericin B  Cured 
20  French Guyana  Work stay  M  22  L. braziliensis complex  Liposomal amphotericin B  Cured 
21  Guatemala  Tourist  M  31  L. mexicana  Ketoconazole  Cured 
22  Peru  Work stay  F  25  L. braziliensis complex  Liposomal amphotericin B  Cured 
23  Peru  Tourist  F  33  L. braziliensis complex  Liposomal amphotericin B  Cured 
24  Peru  Tourist  M  35  L. braziliensis complex  Liposomal amphotericin B  Cured 
Asia   
25  Afghanistan  Immigrant  M  21  L. tropica  Aminosidine ointment  No cure 
26  Afghanistan  Tourist  F  12  n.d.  Aminosidine ointment  Cured 
27  United Arab Emirates  Tourist  F  44  n.d.  Perilesional pentavalent antimonials  Cured 
28  Syria  Tourist  M  5  n.d.  Perilesional pentavalent antimonials  Unknown 
29  Syria  Tourist  F  3  n.d.  Perilesional pentavalent antimonials  Unknown 
30  Turkey  Tourist  F  33  n.d.  Antibiotic  Cured 
31  Turkey  Tourist  M  37  L. donovani complex  Liposomal amphotericin B  Improved 
Africa   
32  Egypt  Tourist  M  25  L. tropica  Aminosidine ointment  No cure 
33  Egypt  Tourist  F  27  L. tropica  Aminosidine ointment  Cured 
34  Kenya  Tourist  M  50  n.d.  Perilesional pentavalent antimonials  Cured 
35  Lybia  Work stay  M  34  n.d.  Aminosidine ointment  Cured 
an.d., not done; IFN, interferon. manial infections in Germany did not exist until 2000
(5–7). Our recent surveillance is dependent on passive
consultation and reporting and therefore may have selec-
tion bias because if visceral leishmaniasis, a potentially
fatal disease that requires hospitalization, is suspected,
advice on diagnosis and treatment is sought more often
than for the skin infection. We assume that our system cap-
tures approximately half of the visceral leishmaniasis
cases and approximately one third of the classical cuta-
neous cases imported to Germany.  
A total of 47% of all cases, but 78% of the visceral
cases were contracted in the European Mediterranean area
and Portugal, and most of the infections indicated a species
of the L. donovani complex, most probably L. infantum, as
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Table 2. Characteristics of patients with visceral leishmaniasis, Germany  
No.  Exposure  Status  Sex  Age  Risk factor 
Leishmania 
species  Treatment  Outcome 
1  Italy  Tourist  M  2 y  Child  n.d.  Liposomal amphotericin B  Cured 
2  Italy  Tourist  F  5 y  Child  n.d.  Liposomal amphotericin B  Cured 
3  Italy  Tourist  M  11 y  Child  n.d.  Liposomal amphotericin B  Cured 
4  Spain  Tourist  F  8 mo  Child  n.d.  Liposomal amphotericin B  Cured 
5  Spain  Tourist  M  9 mo  Child  L. donovani 
complex 
Liposomal amphotericin B  Cured 
6  Iran  Immigrant  M  7 y  Child  L. donovani 
complex 
Liposomal amphotericin B  Cured 
7  Spain  Tourist  M  43 y  HIV  L. donovani 
complex 
Liposomal amphotericin B; 
maintenance therapy: 
HAART plus liposomal 
amphotericin B once monthly 
No relapse for 6 
months 
8  Spain (Ibiza)  Tourist  M  48 y  HIV  L. donovani 
complex 
Liposomal amphotericin B; 
maintenance therapy: 
HAART plus liposomal 
amphotericin B once monthly 
No relapse for 8 
months 
9  Portugal  Visitor  M  29 y  HIV  n.d.  Liposomal amphotericin B; 
maintenance therapy: 
HAART plus liposomal 
amphotericin B once monthly 
unknown 
10  France  Tourist  M  31y  HIV  L. donovani 
complex 
Liposomal amphotericin B; 
maintenance therapy: 
HAART plus liposomal 
amphotericin B once monthly 
Relapse after 4 
months; 
retreatment with 
liposomal 
amphotericin B; No 
relapse for 3 
months 
11  Angola  Immigrant  M  40 y  HIV  L. donovani 
complex 
Systemic pentavalent 
antimonials; maintenance 
therapy: HAART  
plus pentavalent antimonials 
once monthly 
unknown 
12  Togo  Immigrant  M  37 y  HIV  L. donovani 
complex 
Liposomal amphotericin B  Cured 
13  Italy (Sicily)  Visitor  M  31 y  Thymoma  n.d.  Liposomal amphotericin B  Cured 
14  Italy (Ischia)  Tourist  M  67 y  Methotrexate/steroids  L. donovani 
complex 
Liposomal amphotericin B  Cured 
15  Italy (Sicily)  Tourist  M  68 y  Methotrexate  n.d.  Liposomal amphotericin B  Cured 
16  Italy (Ischia)  Tourist  M  70 y  Splenectomy  n.d.  Liposomal amphotericin B  Cured 
17  Spain  Tourist  M  51 y  Splenectomy  L. donovani 
complex 
Liposomal amphotericin B  Cured 
18  Greece 
(Korfu) 
Tourist  M  66 y  Diabetes mellitus 
Hypertonus 
n.d.  Liposomal amphotericin B  Cured 
19  Spain  Tourist  M  52 y  Hypertonus 
Hypercholesterolemia 
n.d.  Liposomal amphotericin B  Cured 
20  Greece 
(Korfu) 
Tourist  M  45 y  Diabetes mellitus 
Emphysema 
L. donovani 
complex 
Systemic pentavalent 
antimonials 
Cured 
21  Tunisia  Tourist  M  53 y  Hypertonus  L. donovani 
complex 
Liposomal amphotericin B  Cured 
22  Malta  Tourist  F  55 y  -  n.d.  Liposomal amphotericin B  Cured 
23  China  Tourist  M  67 y  -  n.d.  Liposomal amphotericin B  Cured 
an.d., not done; HAART, highly active anti-retroviral therapy. the probable causative agent. Thirteen infections (22%)
were acquired on the Mediterranean islands of Ibiza,
Ischia, Majorca, Malta, Korfu, or Sicily. 
This distribution reflects the fact, that the
Mediterranean countries, Spain, Italy, and the
Mediterranean islands, in particular, are the favorite vaca-
tion areas for Germans. Annually, Germans take 18 million
vacations to the European Mediterranean area (including 8
million to Spain and 6 million to Italy) with a median dura-
tion of 2 weeks. Sixty percent of travel to Italy and 90% of
travel to Spain are to Leishmania-endemic areas. 
While leishmaniasis has always been endemic in the
Mediterranean countries, the maximum northern latitude
for sandfly survival is speculated to move further to the
North, beyond Germany (1) because of global warming. If
this scenario is correct, the imported cases may serve as a
potential substrate for the sandfly vector. Dogs that are
imported as pets from the disease-endemic areas of south-
western Europe or that contract the infection when accom-
panying their owners for vacation are another potential
substrate (8). 
Infections with L. infantum in a child, as well as in a
horse who had never left Germany, have recently been
described and have led to speculations about an autochtho-
nous focus (9,10). Also recently, the first sandfly species,
Phlebotomus mascittii Grassi, 1908, was detected in south-
ern Germany, although its potential as a vector of
Leishmania remains to be demonstrated (11).
As expected, visceral leishmaniasis is often manifested
in persons with impaired immunocompetence because of
young age, HIV infection, immunosuppressive therapy and,
in our analysis, in older persons with concomitant diseases.
Notably, 12 (67%) of 18 of the visceral cases contracted
in the European Mediterranean area were in adults, thus
confirming a change in age groups affected. Formerly, vis-
ceral leishmaniasis was known mainly as a disease of chil-
dren (1,2). This change may partly be explained by the
increased proportion of Leishmania and HIV–co-infected
persons and partly by increased travel activities of otherwise
immunocompromised persons, including elderly persons.
Furthermore, even in patients with cutaneous leishma-
niasis, dissemination of parasites has to be excluded in
case of impaired immunocompetence (e.g., immunosup-
pressive treatment). In these cases, Leishmania-specific
PCR of the buffy coat of the peripheral blood is a sensitive
method for detecting parasite spread beyond the skin.
Parents of small children and persons with reduced
immunocompetence should be informed about their
increased susceptibility to infection with Leishmania when
traveling to disease-endemic areas. Measures to reduce the
exposure to sandflies, such as clothes, repellents, and mos-
quito nets as well as collars impregnated with repellents
for accompanying dogs, should be recommended.
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